Business Context and Reporting Period
Company: Arrowhead Research Corporation (a development-stage nanotechnology holding company).
Filing Type: Form 10-Q (Quarterly Report).
Period Ended: December 31, 2009.
Business Overview: The Company forms, acquires, and operates subsidiaries commercializing nanotechnologies in electronics and biotech. Key majority-owned subsidiaries include Unidym (carbon nanotubes) and Calando Pharmaceuticals (oncology drug delivery). The Company also holds minority investments in Nanotope and Leonardo Biosystems. As of December 31, 2009, the Company had 11 full-time corporate employees and 10 at subsidiaries.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2009 | Three Months Ended Dec 31, 2008 |
|---|---|---|
| Revenue | $148,068 | $701,723 |
| Operating Loss | $(2,160,218) | $(8,576,284) |
| Net Loss (Attributable to Arrowhead) | $(1,544,927) | $(8,030,468) |
| Cash and Cash Equivalents (Ending) | $3,809,596 | $7,636,842 |
| Net Cash Used in Operating Activities | $(1,617,843) | $(6,698,514) |
| Total Assets | $9,129,264 | N/A (Balance Sheet not provided for 2008) |
| Total Liabilities | $2,579,789 | N/A |
| Stockholders' Equity | $6,549,475 | N/A |
Debt and Liquidity: The Company reported $3.8 million in cash at period end. Current liabilities totaled $2.6 million, including a $513,620 short-term capital lease obligation and $500,000 in notes payable (reclassified from long-term). The Company raised approximately $3.2 million in a private placement on December 11, 2009.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by approximately 79% to $148,068 from $701,723 in the prior year quarter. This is primarily due to the cessation of significant license fee revenue from Unidym and reduced sales of carbon nanotubes as production is transferred to third parties.
- Significant Loss Reduction: The net loss attributable to Arrowhead decreased by approximately 81% to $1.54 million from $8.03 million. This improvement is driven by aggressive cost-cutting measures, including workforce reductions, closure of Unidym's Texas facility, and Calando's shift from internal clinical trials to a licensing model.
- Expense Reductions:
- Salaries: Decreased from $3.13 million to $1.10 million.
- R&D Expenses: Decreased from $3.89 million to $277,788, largely due to reduced outside lab and contract services at Calando and Unidym.
- G&A Expenses: Decreased from $1.58 million to $746,250, driven by lower legal, patent, and travel costs.
- Discontinued Operations: The Company recorded a gain of $430,000 from the sale of Tego Biosciences assets to Luna Innovations, Inc., which is reported as income from discontinued operations.
Guidance, Outlook, and Risks
Management Commentary & Strategy:
- Cash Conservation: The Company is executing a strategy to conserve cash by scaling down development efforts, seeking out-licensing opportunities, and pursuing partnerships. Management believes current cash reserves, combined with recent financing, are sufficient to fund operations through September 30, 2010, though additional capital may be required.
- Subsidiary Focus: Unidym is focusing on transparent conductive films for touch panels. Calando has closed its lab and is seeking partners for its siRNA delivery platform (CALAA-01) following a Phase I trial.
- Financing: The Company completed a private placement in December 2009 raising $3.2 million. Future funding may come from equity sales, asset sales, or licensing deals.
Risks and Contingencies:
- Liquidity Risk: The Company has a history of losses and requires additional capital to continue operations. Failure to secure funding could force further curtailment of activities.
- NASDAQ Compliance: The Company received a deficiency notice regarding the $1.00 minimum bid price requirement. It is in a 180-day grace period to regain compliance, potentially requiring a reverse stock split.
- Intellectual Property: Unidym's license from Rice University contains solvency covenants. If Unidym becomes insolvent, it could lose rights to critical technology.
- Debt Obligations: Unidym has a capital lease obligation of $513,620 due in monthly installments through July 2010. Calando has a $500,000 convertible note outstanding.
Investor Verification Checklist
- Cash Runway: Verify if the $3.8 million cash balance is sufficient to meet the $513,620 capital lease payments and operating expenses through September 2010 without further dilution.
- NASDAQ Status: Monitor the stock price to determine if a reverse stock split is necessary to maintain NASDAQ listing compliance.
- Subsidiary Licensing: Track progress on Calando's partnership negotiations and Unidym's film sales, as these are critical for future revenue generation.
- Debt Covenants: Review the solvency covenants in Unidym's Rice University license to assess the risk of IP loss if cash flow tightens.
- Dilution: Note the significant number of warrants (approx. 20.7 million) and options outstanding which could dilute existing shareholders in future financings.